The Department of Defense will pay up to $74 million to Evotec’s Seattle-based subsidiary to develop new antibody treatments for orthopoxviruses — a category of pathogens that includes Mpox, formerly known as monkeypox, chickenpox and smallpox.
Per the contract, Just-Evotec Biologics will develop new antibody therapeutics up through first-in-human trials. Evotec CEO Werner Lanthaler declined to disclose how many diseases the deal covers or what diseases are included.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters